Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer

We evaluated AGS-1C4D4, a fully human monoclonal antibody to prostate stem cell antigen (PSCA), with gemcitabine in a randomized, phase II study of metastatic pancreatic cancer. Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and previously untreated, metastatic pancre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2013-07, Vol.24 (7), p.1792-1801
Hauptverfasser:	Wolpin, B.M., O'Reilly, E.M., Ko, Y.J., Blaszkowsky, L.S., Rarick, M., Rocha-Lima, C.M., Ritch, P., Chan, E., Spratlin, J., Macarulla, T., McWhirter, E., Pezet, D., Lichinitser, M., Roman, L., Hartford, A., Morrison, K., Jackson, L., Vincent, M., Reyno, L., Hidalgo, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - secondary Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antigens, Neoplasm - metabolism Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use chemotherapy clinical trial Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease-Free Survival Female Gemcitabine GPI-Linked Proteins - metabolism Humans Kaplan-Meier Estimate Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Liver Neoplasms - mortality Liver Neoplasms - secondary Male metastatic disease Middle Aged Neoplasm Proteins - metabolism Original pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Proportional Hazards Models prostate stem cell antigen Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!